Target Blood Pressure and Combination Therapy: Focus on Angiotensin Receptor Blockers Combination with Either Calcium Channel Blockers or Beta Blockers

被引:1
|
作者
Farag, Selvia M. [1 ]
Rabea, Hoda M. [2 ]
Abdelrahim, Mohamed E. A. [2 ]
Mahmoud, Hesham B. [3 ]
机构
[1] Beni Suef Univ Hosp, Cardiovasc Dept, Bani Suwayf, Egypt
[2] Beni Suef Univ, Fac Pharm, Clin Pharm Dept, Bani Suwayf, Egypt
[3] Beni Suef Univ Hosp, Dept Cardiol, Bani Suwayf, Egypt
关键词
Target blood pressure; combination therapy; hypertension; angiotensin receptor blockers; calcium channel blockers; beta-blockers; FIXED-DOSE COMBINATIONS; HYPERTENSIVE PATIENTS; CARDIOVASCULAR EVENTS; DOUBLE-BLIND; SYSTOLIC HYPERTENSION; HEART-FAILURE; VALSARTAN; TRIAL; MONOTHERAPY; AMLODIPINE;
D O I
10.2174/1573402118666220627120254
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: The target blood pressure has changed many times in the guidelines in past years. However, there is always a question; is it good to lower blood pressure below 120/80 or not? Control of blood pressure in hypertension is very important in reducing hypertension-modified organ damage. So, the guidelines recommend combining more than one antihypertensive drug to reach the target blood pressure goal. Results: Combination therapy is recommended by guidelines to reach the blood pressure goal. The guidelines recommend many combinations, such as the combination of angiotensin receptor blockers with either calcium channel blockers (CCB) or beta-blocker (BB). Angiotensin receptor blocker (ARB) combination with CCB has gained superiority over other antihypertension drug combinations because it reduces blood pressure and decreases the incidence of CV events and organ damage. BB combinations are recommended by guidelines in patients with ischemic events but not all hypertensive patients. Unfortunately, the new generation BB, for example, nebivolol, has a vasodilator effect, making it new hope for BB. Conclusion: Combination therapy is a must in treating the hypertensive patient. The new generation BBs may change the recommendations of guidelines because they have an effect that is similar to CCBs.
引用
收藏
页码:138 / 144
页数:7
相关论文
共 50 条
  • [21] The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors
    Sica, DA
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2002, 3 (02) : 66 - 71
  • [22] A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients
    Yang, Yue
    Wei, Ri-bao
    Xing, Yue
    Tang, Lu
    Zheng, Xiao-yong
    Wang, Zi-cheng
    Gao, Yu-wei
    Li, Min-xia
    Chen, Xiang-mei
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2013, 62 (12): : 1858 - 1866
  • [23] Issues in drug metabolism of major antihypertensive drugs: β-blockers, calcium channel antagonists and angiotensin receptor blockers
    Christian, Hoecht
    Martin Bertera, Facundo
    Alejandro Mayer, Marcos
    Alberto Taira, Carlos
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2010, 6 (02) : 199 - 211
  • [24] Real-world efficacy of fimasartan vs. other angiotensin receptor blockers in combination with calcium channel blockers: a nationwide cohort study
    Lee, Huijin
    Park, Chan Soon
    Kim, Bongseong
    Rhee, Tae-Min
    Lee, Heesun
    Kim, Yong-Jin
    Han, Kyungdo
    Kim, Hyung-Kwan
    CLINICAL HYPERTENSION, 2024, 30 (01)
  • [25] A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention
    Wang, Ji-Guang
    VASCULAR HEALTH AND RISK MANAGEMENT, 2009, 5 : 593 - 605
  • [26] Angiotensin receptor blockers: Focus on cardiac and renal injury
    Arumugam, Somasundaram
    Sreedhar, Remya
    Thandavarayan, Rajarajan A.
    Karuppagounder, Vengadeshprabhu
    Krishnamurthy, Prasanna
    Suzuki, Kenji
    Nakamura, Masahiko
    Watanabe, Kenichi
    TRENDS IN CARDIOVASCULAR MEDICINE, 2016, 26 (03) : 221 - 228
  • [27] Prescription data related to the use of calcium channel blockers, ACE inhibitors and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers) in combination identify savings opportunities
    Carugo S.
    Rossetti G.
    Merlino L.
    Mancia G.
    High Blood Pressure & Cardiovascular Prevention, 2009, 16 (1) : 21 - 26
  • [28] Comparative Study of Metabolite Changes After Antihypertensive Therapy With Calcium Channel Blockers or Angiotensin Type 1 Receptor Blockers
    Lu, Jieyu
    Tian, Yunfan
    Gu, Jia
    Qiu, Ming
    Lu, Yan
    Sun, Wei
    Kong, Xiangqing
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 77 (02) : 228 - 237
  • [29] Beta-Blockers and Calcium Channel Blockers: First Line Agents
    Isaac Pascual
    Cesar Moris
    Pablo Avanzas
    Cardiovascular Drugs and Therapy, 2016, 30 : 357 - 365
  • [30] Evaluation of poisoned children with calcium channel blockers or beta blockers drugs
    Konca, Capan
    Yildizdas, Riza Dincer
    Sari, Mehmet Yusuf
    Yukselmis, Ufuk
    Horoz, Ozden Ozgr
    Yilmaz, Hayri Levent
    TURK PEDIATRI ARSIVI-TURKISH ARCHIVES OF PEDIATRICS, 2013, 48 (02): : 138 - 144